Antimicrobial activity of cefamandole against Salmonella typhi.
A patient with Salmonella typhi bacteremia was sucessfully treated with cefamandole, a new cephalosporin derivative. Infection has not recurred during 6 months of follow-up observation. Minimum inhibitory concentrations and minimum bactericidal concentrations of cefamandole, cephalothin, ampicillin, and chloramphenicol were compared against 26 strains of S. typhi. All the strains were susceptible to cefamandole in vitro. Seven of the strains were resistant to chloramphenicol, and another seven were resistant to both chloramphenicol and ampicillin. Cefamandole appears to warrant further clinical trial for the treatment of typhoid fever.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002511:Cephalosporins / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D012485:Salmonella typhi / Q000187:drug effects; D014435:Typhoid Fever / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins